Table Graph
   

vaccines - versus mRNA vaccine - for COVID-19 prophylaxis (excluding children) pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.09 [0.04, 0.19]< 155%3 studies (-/3)100.0 %moderatenot evaluable moderatecrucial-
hospitalization or death 0.34 [0.15, 0.77]< 159%2 studies (-/2)99.5 %NAnot evaluable crucial-
confirmed COVID (any severity) 0.20 [0.13, 0.32]< 199%10 studies (1/9)100.0 %NAlow important-
hospitalization 0.19 [0.04, 0.98]< 199%7 studies (-/7)97.6 %NAnot evaluable important-
symptomatic Covid-19 0.37 [0.26, 0.54]< 197%3 studies (-/3)100.0 %NAnot evaluable important-
severe COVID-19 (FDA definition) 0.25 [0.01, 5.50]< 10%1 study (1/-)80.8 %NAnot evaluable non important-
severe COVID-19 occurrence 0.06 [0.05, 0.08]< 10%4 studies (1/3)100.0 %NAnot evaluable non important-

safety endpoints 00

adverse events 1.14 [0.78, 1.66]< 10%1 study (1/-)24.7 %NAnot evaluable non important-
arrhythmia 1.99 [0.07, 59.22]< 10%1 study (1/-)34.8 %NAnot evaluable non important-
hypertension 0.50 [0.02, 14.80]< 10%1 study (1/-)65.5 %NAnot evaluable non important-
intracranial hemorrhage 1.44 [0.09, 23.11]< 10%2 studies (1/1)39.9 %NAnot evaluable non important-
ischemic stroke 1.44 [0.09, 23.11]< 10%2 studies (1/1)39.9 %NAnot evaluable non important-
Myocardial infarction 0.97 [0.28, 3.30]< 10%4 studies (3/1)52.2 %lownot evaluable highnon important-
pulmonary embolism 0.53 [0.07, 4.06]< 10%3 studies (2/1)72.8 %NAnot evaluable non important-
serious adverse events (SAE), any 1.53 [0.25, 9.36]< 10%1 study (1/-)32.3 %NAnot evaluable non important-
stroke (non-specific, hemorrhagic, and ischemic) 0.99 [0.06, 15.88]< 10%1 study (1/-)50.2 %NAnot evaluable non important-
venous thromboembolism 2.03 [0.07, 61.21]< 10%1 study (1/-)34.4 %NAnot evaluable non important-

AE of interest endpoints 00

cerebral venous sinus thrombosis (CVST) 0.50 [0.02, 14.80]< 10%1 study (1/-)65.5 %NAnot evaluable important-
appendicitis 3.97 [0.18, 88.14]< 10%1 study (1/-)19.4 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons